Find It First
TriageIQ™
Universal Chronic Screener
TriageIQ™ | The Universal Chronic Disease Screener.
Find It First
TriageIQ™
Universal Chronic Screener
Screening for Chronic Diseases
TriageIQ™ is a proprietary evidence-based 1–2 minute universal chronic screener and the only intake tool that simultaneously identifies early neurological, cardiometabolic, and behavioral risk signals, generating Medicare-ready medical necessity documentation and a structured clinical pathway in a single interaction.
Unlike the MoCA, PHQ-9, and GAD-7 — each limited to one condition, one domain, and one purpose — TriageIQ™ aggregates early neurological, cardiometabolic, and behavioral risk signals simultaneously, replacing multiple free tools with one proprietary solution, and does what no free tool can: turn every chronic care screening into a documented, reimbursable clinical event that activates the downstream pathways that follow.
"In initial clinical use, providers identified an average of 2 additional reimbursable assessments per patient visit."
Medical clinics, healthcare organizations, provider networks, and technology platforms gain a scalable system that finds what others miss — improving compliance, reducing labor hours, lowering staffing costs, and eliminating administrative burden — while generating the downstream revenue pathways that free tools simply cannot produce.
Closing Medicare's Documentation Gap
Patients can complete TriageIQ™ screenings on-site or remotely— no special equipment required.
TriageIQ™ is a proprietary evidence-based Universal Chronic Screener built on a cognitive screening methodology with over two years of clinical use — requiring no equipment or specialized training, adding virtually no workflow time, and producing structured, objective results with a documented clinical pathway.
Developed and owned exclusively by Diabetes Testing Centers™, TriageIQ™ deploys seamlessly in-clinic, remotely, through telemedicine, digital platforms, or AI voice integration — simultaneously identifying three early risk signal areas that free tools like the MoCA, PHQ-9, and GAD-7 address only in isolation:
Early Neurological Risk — identifying thinking ability changes, executive function decline, cognitive impairment markers, neuropathy indicators, and fall risk signals that establish medical necessity for further neuropsychological evaluation
Early Cardiometabolic Risk — identifying vascular, metabolic, and cardiovascular risk indicators associated with chronic disease including diabetes, metabolic syndrome, hypertension, and obesity before complications occur
Early Behavioral Risk — identifying behavioral health indicators including depression, anxiety, and psychological risk factors associated with chronic disease that significantly impact clinical outcomes and care plan adherence
Unlike tools limited to a single domain, TriageIQ™ aggregates all three risk signal areas simultaneously — turning every chronic care interaction into a documented, Medicare-ready clinical event that identifies what others miss and activates the reimbursable pathways that follow, including cognitive assessments, behavioral assessments, and individualized cognitive care plans.
Grounded in peer-reviewed clinical evidence, published research consistently demonstrates that patients with diabetes, hypertension, metabolic syndrome, and cardiovascular disease face significantly elevated risk of neurological, cardiometabolic, and behavioral health deterioration — risks that go undetected in the majority of chronic care interactions today.
Early detection saves lives. TriageIQ™ makes it possible.
See What Others Miss
Most neurological, cardiometabolic, and behavioral risk in chronic disease patients goes undetected until significant damage has already occurred. TriageIQ™ changes that by equipping providers with a fast, objective, and documentable Universal Chronic Screener that identifies at-risk patients earlier, when intervention is still most effective and damage is still preventable.
Most screening tools are deployed selectively — applied only to patients already suspected of risk. This approach misses the majority of the at-risk population because chronic disease patients frequently do not present with obvious neurological, cardiometabolic, or behavioral symptoms until significant and often irreversible damage has already occurred. Waiting for symptoms is not early detection. It is late response.
TriageIQ™ is designed to screen every patient, every month, in 1–2 minutes — as a standard embedded component of any existing clinical interaction, AI voice platform, or telemedicine workflow. This universal application model means:
No patient is overlooked due to provider assumption or time constraints
Early neurological, cardiometabolic, and behavioral risk is identified before symptoms appear
Structured documentation is generated for every interaction regardless of outcome
Medical necessity is established proactively rather than reactively
Every chronic care interaction becomes a documented clinical screening event
The peer-reviewed evidence supporting this approach is substantial. Studies consistently demonstrate that neurological, cardiometabolic, and behavioral decline in chronic disease populations — particularly diabetes, cardiovascular disease, hypertension, and metabolic syndrome — begins years before clinical presentation. A universal monthly screener is the only model that captures this risk at the scale modern chronic care platforms operate.
TriageIQ™ is the missing aggregator layer the chronic care industry has needed. A proprietary, universal, AI-ready Universal Chronic Screener that simultaneously identifies early neurological, cardiometabolic, and behavioral risk signals across the entire chronic disease population — before further evaluation is warranted, before symptoms appear, and before damage becomes irreversible.
Alzheimer's is Underdiagnosed & Undertreated
Every Chronic Patient—Every Time
Medicare's documentation requirements have never been stricter. CMS now expects a clearly documented clinical pathway demonstrating why neurological, cardiometabolic, or behavioral testing was medically justified — and general observations or vague nurse notes are no longer sufficient during audits.
This is not a challenge limited to one care setting. It affects every organization managing chronic disease patients at scale — and the consequences of inadequate documentation are the same regardless of size: audit exposure, claim denials, and lost revenue.
TriageIQ™ was purpose-built to solve this problem across every setting simultaneously.
In a single 1–2 minute interaction TriageIQ™ automatically generates a structured digital transcript capturing the specific neurological, cardiometabolic, and behavioral risk indicators identified during the screening — creating four critical advantages no free tool provides:
Objective, standardized documentation for every patient interaction regardless of outcome
A clear, defensible clinical pathway establishing medical necessity for further evaluation
An audit-proof trail grounded in proprietary evidence-based screening logic
Consistent documentation quality whether the interaction is conducted by clinical staff, telemedicine, or AI
Because TriageIQ™ deploys within any electronic, digital, or AI-enabled interface — including voice, text, and EHR integration — it functions identically across an independent primary care practice, a large health system, a remote patient monitoring platform, a behavioral health program, and a specialty diagnostic technology company without requiring changes to existing workflows.
The result is transformative. Every monthly CCM or RPM interaction becomes more than a routine check-in — it becomes a documented clinical screening event that identifies early risk, establishes medical necessity, protects every organization in the care continuum from audit exposure, and simultaneously expands the reimbursable services available to every patient in the chronic disease population. TriageIQ™ was built to change that fact.
Early Detection Saves Lives Sooner
TriageIQ™ is a trademark of Medrano & Associates LLC dba Diabetes Testing Centers™. All rights reserved. Proprietary screening methodology is protected intellectual property.